I have reviewed consultations where practitioners prescribed niacinamide and azelaic acid for severe comedonal acne and waited months for results that never came. The morphology told a different story. Building an effective acne treatment plan starts with reading what is actually on the skin before reaching for the pen.
The Four Pathophysiological Drivers
NICE NG198 describes acne vulgaris as a disease of the pilosebaceous unit with four interlocking drivers: excess sebum production, follicular hyperkeratosis, proliferation of Cutibacterium acnes, and the subsequent inflammatory cascade. An effective treatment plan targets the driver that is dominant in your patient's presentation.
Sebum excess is under androgenic control. This is why acne flares during puberty, worsens premenstrually in women, and persists in patients with polycystic ovary syndrome. When a patient reports persistently oily skin and closed comedones across the forehead and chin, excess sebum production is the clinical starting point.
Follicular hyperkeratosis produces comedones. Open comedones (blackheads) and closed comedones (whiteheads) represent retained follicular material without significant inflammation. Inflammatory lesions come later: papules, pustules, nodules. Identifying which morphological type dominates guides your first-line prescription.
Mapping Morphology to Treatment
Practitioners who treat inflammatory acne and comedonal acne with the same protocol will consistently underperform.
Predominantly comedonal (non-inflammatory): Topical retinoids are first-line. NICE NG198 recommends a topical retinoid, with or without benzoyl peroxide, as the initial approach for comedonal and mild-to-moderate papulopustular acne. Retinoids normalise follicular keratinisation and reduce microcomedone formation at the root. Adapalene 0.1% gel has the most tolerability evidence for starting treatment in an aesthetic practice setting.
Mild-to-moderate papulopustular (inflammatory): A topical retinoid combined with benzoyl peroxide. NICE recommends this combination over topical antibiotics alone, to reduce the risk of antimicrobial resistance. Benzoyl peroxide is directly bactericidal against C. acnes and does not generate resistance, which makes it a key part of any long-term plan.
Moderate-to-severe nodular or widespread disease: This is the point where referral or collaborative prescribing becomes the appropriate decision for most aesthetic practitioners. Oral antibiotics, combined oral contraceptives, and oral isotretinoin sit within this tier. Knowing where your scope of practice ends is part of the consultation, not a failure of it.
The Consultation Structure That Works
I use a consistent framework for every new acne patient.
Clarify the history. When did it start? Is it cyclical? What has been tried, and for how long? Many patients arrive having abandoned a retinoid after ten days because of the initial purge response. Duration matters more than product name.
Assess distribution and morphology. Forehead and nose (T-zone, sebum-dominant), jawline and chin (frequently hormonal, particularly in adult women), and cheeks (more often barrier-related or contact factor-driven) respond to different approaches. Map the distribution before prescribing.
Grade the acne. NICE NG198 uses a three-tier classification: mild, moderate, and severe, based on lesion count and type. Grading at baseline gives you a reference point for every follow-up. Without it, you are measuring progress against memory.
Assess the skin barrier. A compromised barrier cannot tolerate high-strength retinoids or daily benzoyl peroxide from day one. Introducing both simultaneously in sensitised skin drives treatment dropout before any improvement is seen. If there is significant dryness, redness, or reactivity, stabilise the barrier first.
Set realistic expectations. NICE NG198 notes that topical treatments typically require six to eight weeks before meaningful improvement appears, and twelve weeks for full assessment. Most patients who abandon treatment do so before the eight-week mark. I communicate this at every first appointment, in writing as well as verbally.
Where Clinical Evidence Is Still Developing
NICE NG198 does not recommend specific dietary changes as first-line management for acne. The evidence base for low-glycaemic-index diets and reduced dairy intake is growing but remains heterogeneous in quality, and current guidance does not support prescribing dietary change in place of established topical treatments. This is worth discussing with patients who ask directly, without overstating what the evidence can currently support.
The growing literature on the cutaneous microbiome and Cutibacterium acnes strain diversity is relevant to understanding why identical presentations respond differently to similar treatments. Some strains are consistently associated with inflammatory acne; others appear commensal and possibly protective. This is an emerging area, not yet at clinical guidance level, but it adds context to why antibiotic stewardship in acne management matters and why benzoyl peroxide matters more than it might appear.
Building the Plan: One Treatment at a Time
The most effective acne plans I have built are not the most complex ones. They start with one or two interventions, give them adequate time, and build from there. Patients who arrive with ten active products rarely have a reliable sense of what is working. Simplicity creates accountability on both sides of the consultation.
If you want to deepen your systematic approach to acne assessment and treatment planning, Acne Decoded at Aesthetics Unlocked covers morphology classification, treatment selection, consultation structure, and the evidence base for each decision in a format built for clinical practice. You can find it at aestheticsunlocked.co.uk/courses/acne-decoded.